Objectives Comprehensive economic costs of multiple sclerosis (MS) according to EDSS
states can only be assessed by evaluating MS management in real clinical practice. The …

Background Little is known of how the cost of illness and health-related quality of life
changes over time after a diagnosis of multiple sclerosis. Objectives The aim was thus to …

Background: Multiple sclerosis (MS) is the most common chronic, non-traumatic, neurologic
disease in young adults. While approximate values of the disease burden of MS are known …

Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …

Background Estimating multiple sclerosis (MS) prevalence and incidence, and assessing
the utilisation of disease-modifying therapies (DMTs) and healthcare resources over time is …

Background: The current focus in multiple sclerosis (MS) is on early diagnosis and drug
intervention, with a view to modifying disease progression. Consequently, healthcare costs …

Background Most of the knowledge about people with multiple sclerosis (PwMS) in France
comes from cohorts, which may suffer from recruitment bias or from the unique registry …

Background Disease modifying treatments (DMTs) are the main responsible for direct
medical costs in multiple sclerosis (MS). The current investigation aims at evaluating …

Background and Objectives Multiple sclerosis (MS), a leading cause of nontraumatic
neurologic disability in young adults, exerts a substantial economic burden on the health …

Interest of the work Multiple sclerosis (MS) disease modifying therapies (DMT) utilization
increased during the last decade with the approval of new drugs. Symptomatic treatments …